Amphastar: Diversified Growth Offsets IMS Headwind

Warning letter at IMS tempers otherwise strong quarter of launches, BAQSIMI milestone, and pipeline progress.

AMPH · Earnings Call · 2026-08-06

A Quarter of Balancing Acts

Amphastar's Q2 2026 report painted a picture of a company successfully threading the needle: growth from Ipratropium Bromide and an expanding commercial portfolio offset declines in legacy generics, while a newly-received FDA warning letter at its IMS subsidiary adds an unresolved overhang. Revenue rose 5% year-over-year to $183.9 million, as CFO William Peters detailed: “Revenues for the second quarter increased 5% to $183.9 million from $174.4 million in the previous year's period.” — William Peters, Chief Financial Officer · 2026-08-06 The launch of ipratropium bromide inhalation (AMP-007) in April contributed $8.4 million in its first quarter on the market, while iron sucrose and teriparatide added $3.5 million and $4.5 million respectively. These newer, higher-margin products helped lift gross margin to 51% from 50% a year ago. BAQSIMI remains the franchise to watch. Prescriptions grew 17% year-over-year, though net sales dipped 3% to $45.5 million, hit by pricing, rebates, and 340B dynamics. Management is actively tackling the duplicate-discount problem: “In May, in response to these pricing dynamics we had seen over the past few quarters, we engaged a third party to support data-driven identification, validation, and resolution of potential 340B duplicate discounts, which led to a smaller impact than we saw in the first quarter.” — William Peters, Chief Financial Officer · 2026-08-06 The quarter also triggered the first annual sales milestone under the Lilly agreement—exceeding $175 million in net sales—which will require a $100 million payment in Q3. On the prior call, CFO Peters had flagged the 340B issue and expected mitigation: “we believe that we could get at least part way back to the pricing where we were last year or most of the way back later this year.” — William Peters, Chief Financial Officer · 2026-05-08 That thesis is now playing out, though halfway there.

IMS: A Manageable Yet Persistent Overhang

A central focus of the call was the FDA warning letter received at IMS, a subsidiary that contributes roughly a third of total revenue. Management was careful to frame it as a remediation exercise rather than a business interruption:

The warning letter does not require IMS to stop manufacturing or distributing its products. While the remediation effort will require additional resources, at this time, we do not currently anticipate a material adverse effect on Amphastar's overall business operations, commercial portfolio, development pipeline, or sales.
Dan Dischner, Chief Executive Officer · 2026-08-06

CFO Peters quantified the cost: “Due to remediation efforts at our IMS facility, we expect expenses there will increase by $2 million to $3 million per quarter for the next several quarters.” — William Peters, Chief Financial Officer · 2026-08-06 He also noted that while IMS sales are slowing slightly as quality reviews intensify, the company maintains its overall corporate sales guidance of mid- to high-single-digit growth. This is a classic case of a regulatory overhang that is being managed through incremental investment rather than a strategic unwind—though continued FDA scrutiny will keep it in the spotlight.

Pipeline Progress and BD Discipline

The longer-term story rests on the pipeline. Insulin Aspart (AMP-004) remains on track for a 2027 launch, with a bioavailability study recently completed on ClinicalTrials.gov. CFO Peters confirmed: “we're on schedule for that to have our commercial launch of the product next year in 2027.” — William Peters, Chief Financial Officer · 2026-08-06 At the same time, management was candid about margins—expecting insulin aspart to come in at or slightly below corporate gross margins—but highlighted meaningful sales potential. Beyond AMP-004, the company has initiated Phase I for AMP-101 (nasal epinephrine), and AMP-109 is in non-clinical studies, while AMP-110 (corticotropin) and AMP-107 (eye drop) advance toward INDs. Business development remains a priority, with a clear preference for immediately accretive or late-stage assets, though the door is open to early-stage opportunities in oncology, ophthalmology, and immunology—the same verticals as its in-licensed portfolio from last year.

Financial Trajectory

The quarter showed a clear recovery in profitability after a weak Q1. Adjusted net income was flat at $40.8 million, but per-share adjusted EPS rose to $0.91 from $0.85, reflecting continued buybacks. Operating cash flow was $51.3 million, and the company repurchased ~$45 million worth of shares, accelerating its capital return program. The fundamentals snapshot from Q1 shows the volatility management is working against: Gross margin in Q2 reached 51%, up from 41% in Q1, driven by high-margin launches like ipratropium, teriparatide, and iron sucrose, according to management. The company’s blended gross margin trajectory remains volatile as product mix shifts. The stock itself has been in a long drawdown from its 2023 peak, but the recent 90-day trend is slightly positive (+6%), suggesting investors are starting to give credit for the execution. Overall, Amphastar’s story is one of diversification paying off in real time—new launches cushioning legacy declines—while the IMS remediation adds a manageable but persistent uncertainty. The reaffirmed guidance and milestone achievement provide tangible evidence that the thesis is intact, even as the market waits for IMS to fully clear.